File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

TitleChinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Authors
Issue Date2020
Citation
Journal of Medicinal Chemistry, 2020, v. 63, n. 22, p. 13205-13227 How to Cite?
AbstractThe coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to more than 20 million people infected worldwide with an average mortality rate of 3.6%. This virus poses major challenges to public health, as it not only is highly contagious but also can be transmitted by asymptomatic infected individuals. COVID-19 is clinically difficult to manage due to a lack of specific antiviral drugs or vaccines. In this article, Chinese therapy strategies for treating COVID-19 patients, including current applications of traditional Chinese medicine (TCM), are comprehensively reviewed. Furthermore, 72 small molecules from natural products and TCM with reported antiviral activity against human coronaviruses (CoVs) are identified from published literature, and their potential applications in combating SARS-CoV-2 are discussed. Among these, the clinical efficacies of some accessible drugs such as remdesivir (RDV) and favipiravir (FPV) for COVID-19 are emphatically summarized. We hope this review provides a foundation for managing the worsening pandemic and developing antivirals against SARS-CoV-2.
Persistent Identifierhttp://hdl.handle.net/10722/311946
ISSN
2023 Impact Factor: 6.8
2023 SCImago Journal Rankings: 1.986
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChoudhry, Namrta-
dc.contributor.authorZhao, Xin-
dc.contributor.authorXu, Dan-
dc.contributor.authorZanin, Mark-
dc.contributor.authorChen, Weisan-
dc.contributor.authorYang, Zifeng-
dc.contributor.authorChen, Jianxin-
dc.date.accessioned2022-04-06T04:31:49Z-
dc.date.available2022-04-06T04:31:49Z-
dc.date.issued2020-
dc.identifier.citationJournal of Medicinal Chemistry, 2020, v. 63, n. 22, p. 13205-13227-
dc.identifier.issn0022-2623-
dc.identifier.urihttp://hdl.handle.net/10722/311946-
dc.description.abstractThe coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to more than 20 million people infected worldwide with an average mortality rate of 3.6%. This virus poses major challenges to public health, as it not only is highly contagious but also can be transmitted by asymptomatic infected individuals. COVID-19 is clinically difficult to manage due to a lack of specific antiviral drugs or vaccines. In this article, Chinese therapy strategies for treating COVID-19 patients, including current applications of traditional Chinese medicine (TCM), are comprehensively reviewed. Furthermore, 72 small molecules from natural products and TCM with reported antiviral activity against human coronaviruses (CoVs) are identified from published literature, and their potential applications in combating SARS-CoV-2 are discussed. Among these, the clinical efficacies of some accessible drugs such as remdesivir (RDV) and favipiravir (FPV) for COVID-19 are emphatically summarized. We hope this review provides a foundation for managing the worsening pandemic and developing antivirals against SARS-CoV-2.-
dc.languageeng-
dc.relation.ispartofJournal of Medicinal Chemistry-
dc.titleChinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1021/acs.jmedchem.0c00626-
dc.identifier.pmid32845145-
dc.identifier.scopuseid_2-s2.0-85096885060-
dc.identifier.volume63-
dc.identifier.issue22-
dc.identifier.spage13205-
dc.identifier.epage13227-
dc.identifier.eissn1520-4804-
dc.identifier.isiWOS:000595545900002-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats